"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 7 | 16 | 23 |
| 1996 | 4 | 11 | 15 |
| 1997 | 4 | 7 | 11 |
| 1998 | 6 | 16 | 22 |
| 1999 | 10 | 18 | 28 |
| 2000 | 7 | 12 | 19 |
| 2001 | 14 | 20 | 34 |
| 2002 | 11 | 14 | 25 |
| 2003 | 15 | 15 | 30 |
| 2004 | 23 | 16 | 39 |
| 2005 | 25 | 19 | 44 |
| 2006 | 26 | 15 | 41 |
| 2007 | 30 | 13 | 43 |
| 2008 | 21 | 21 | 42 |
| 2009 | 31 | 19 | 50 |
| 2010 | 38 | 22 | 60 |
| 2011 | 19 | 12 | 31 |
| 2012 | 17 | 11 | 28 |
| 2013 | 18 | 9 | 27 |
| 2014 | 17 | 12 | 29 |
| 2015 | 13 | 7 | 20 |
| 2016 | 15 | 6 | 21 |
| 2017 | 27 | 10 | 37 |
| 2018 | 22 | 14 | 36 |
| 2019 | 19 | 10 | 29 |
| 2020 | 14 | 13 | 27 |
| 2021 | 10 | 17 | 27 |
| 2022 | 4 | 19 | 23 |
| 2023 | 2 | 9 | 11 |
| 2024 | 14 | 5 | 19 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
-
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
-
Mutability and hypermutation antagonize immunoglobulin codon optimality. Mol Cell. 2025 Jan 16; 85(2):430-444.e6.
-
Novel Antibody-Based Protection/Therapeutics in Staphylococcus aureus. Annu Rev Microbiol. 2024 Nov; 78(1):425-446.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 09 26; 391(12):1119-1129.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication. Oncologist. 2024 Sep 06; 29(9):806-810.
-
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
-
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928.